Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

INDUSTRY × Neurofibromatoses × mirdametinib × Clear all

Phase

Status

Available 1 Active not recruiting 1

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1 Expanded_access 1

Sponsor

Cancer Type

Conditions

Neurofibromatoses 2 Neurofibroma, Plexiform 2 Neurofibromatosis 1 1 Neurofibroma 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumor 1

Interventions

mirdametinib 2 emvododstat 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03962543 2025-08-07

ReNeu

SpringWorks Therapeutics, Inc.

Phase 2 Active not recruiting

114 enrolled 25 charts 1 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT05028166 2024-03-15

Individual Patient Compassionate Use of Mirdametinib

SpringWorks Therapeutics, Inc.

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡